Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hayley Widden
Observed name:
Hayley N. Widden
Institution:
Natera (United States)
Observed institutions:
University of Alabama at Birmingham,
Natera (United States)
OpenAlex ID:
A5034446770
The multiple mechanisms of MCL1 in the regulation of cell fate
2021
·
Hayley Widden
, William J. Placzek
·
Communications Biology
·
163
PDF
A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma
2020
·
Nicholas J. Eustace
, Joshua C. Anderson
, et al.
·
Oncogene
·
19
MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73
2020
·
Hayley Widden
, Aneta Kaczmarczyk
, et al.
·
Cell Death and Disease
·
18
PDF
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma
2024
·
Mayur Narkhede
, Sarah Tomassetti
, et al.
·
Frontiers in Oncology
·
12
l-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models
2024
·
Anirban Kundu
, Garrett J. Brinkley
, et al.
·
Journal of Clinical Investigation
·
9
Role of Circulating Tumor DNA As a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma
2023
·
Mayur S. Narkhede
, Sarah Tomassetti
, et al.
·
Blood
·
3
MP12-02 PROSPECTIVE EVALUATION OF CIRCULATING TUMOR DNA (ctDNA) IN DETECTING EARLY PROGRESSION ON IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED GENITOURINARY CANCERS
2022
·
Albert Jang
, Ellen Jaeger
, et al.
·
The Journal of Urology
·
1
Abstract 2498: MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73
2019
·
Hayley Widden
, Aneta Kaczmarczyk
, et al.
·
Cancer Research
·
1
Exth-52. Use of a Phospholipid Binding Marcks Mimetic for Targeted Killing of Glioblastoma Cells
2018
·
Nicholas Eustace
, Jason Warram
, et al.
·
Neuro-Oncology
·
1
PDF
ABCL-573: ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma
2026
·
Basem William
, Natalie Galanina
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-573: ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma
2026
·
Basem William
, Natalie Galanina
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma
2026
·
Natalie Galanina
, Madiha Iqbal
, et al.
·
Blood Neoplasia
Abstract 3705: L-2HG, oncometabolite-driven epigenetic and epitranscriptomic reprogramming creates metabolic vulnerability in renal cancer
2023
·
Anirban Kundu
, Garrett J. Brinkley
, et al.
·
Cancer Research
Pd17-08 Epigenetic and Epitranscriptomic Reprogramming in Renal Cancer by Oncometabolite L-2hg Creates Metabolic Vulnerability
2023
·
Garrett Brinkley
, Anirban Kundu
, et al.
·
The Journal of Urology
Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma
2022
·
Mayur Narkhede
, Sarah Tomassetti
, et al.
·
Blood
Inhibition of the SET/MLL Histone Methyltransferase Complex as a Novel Epigenetic Targeted Therapy in Mixed Lineage Leukemia
2021
·
Hayley Widden
, Omar Moukha‐Chafiq
, et al.
·
The FASEB Journal
Transcriptional Activation of Tumor Suppressor p73 is Modulated by MCL1 Through a Novel Protein Interaction
2020
·
Hayley Widden
, Aneta Kacmarczyk
, et al.
·
The FASEB Journal
Abstract 2498: MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73
2019
·
Hayley Widden
, Aneta Kaczmarczyk
, et al.
·
Molecular and Cellular Biology / Genetics
Show more works
View as search
Works count:
18
Citation count:
227
H-index:
5
I10-index:
4
Year
Topic
Type
